Company filings, made visual.

Find a company. Follow its revenue through costs and profit.

Market

Find a company or ticker

Coverage includes separate ticker and security records; counts are not unique companies.

Penumbra, Inc.

PEN

Filing: SEC 10-Q
Period: Three months ended March 31, 2026
Basis: Editorial filing; Read original SEC 10-Q ↗

Sankey diagram of Penumbra, Inc.. A complete text table follows the diagram.

Penumbra Converts Neurovascular and Vascular Devices Into Revenue

Penumbra's medical-device platform is represented by consolidated product revenue.

Swipe to explore

Source & review

Read original SEC 10-Q ↗

SEC accession: 0001321732-26-000019
Filed: Date not recorded
Reviewed: Date not recorded
Status: Individual filing review complete

How to read these figures

Labels and displayed flow values are reported filing values or exact disclosed subtotals.

Labels and narrative explain the filing. A category marked “arithmetic bridge” or “residual” is calculated from reported totals, rather than a separately reported line.

The filing reports $374.758M revenue; no unsupported product-category allocation is added.

View accessible tables

Financial categories · Three months ended March 31, 2026 · Millions of USD
Category	Stage	Value	Notes
Penumbra revenue	1	$375M	$374.8M reported quarterly revenue
Neurovascular and vascular devices	2	$375M	Reported revenue

Financial flows · Millions of USD
From	To	Value
Penumbra revenue	Neurovascular and vascular devices	$375M